Systemic Lupus Erythematosus - Pipeline Review, H2 2016

Date: November 16, 2016
Pages: 419
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S6FFC1B00C0EN
Leaflet:

Download PDF Leaflet

Systemic Lupus Erythematosus - Pipeline Review, H2 2016
Systemic Lupus Erythematosus - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Lupus Erythematosus – Pipeline Review, H2 2016, provides an overview of the Systemic Lupus Erythematosus (Immunology) pipeline landscape.

Systemic lupus erythematosus (SLE) is an autoimmune disease that causes a chronic inflammatory condition. The inflammation triggered by SLE affect many organs in the body, including skin, joints, kidneys, brain, and other organs. Several factors have been associated with the disease such as genetics, environment and gender and hormones. Symptoms can vary and can change over time. Common symptoms include severe fatigue, painful or swollen joints, headaches, rash on cheeks and nose called butterfly rash, hair loss and anemia.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Lupus Erythematosus – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Lupus Erythematosus (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 22, 31, 36 and 7 respectively. Similarly, the Universities portfolio in Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 9 and 1 molecules, respectively.Systemic Lupus Erythematosus.

Systemic Lupus Erythematosus (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Systemic Lupus Erythematosus (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Systemic Lupus Erythematosus (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Systemic Lupus Erythematosus (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Lupus Erythematosus (Immunology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Systemic Lupus Erythematosus (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Systemic Lupus Erythematosus Overview
Therapeutics Development
Systemic Lupus Erythematosus - Therapeutics under Development by Companies
Systemic Lupus Erythematosus - Therapeutics under Investigation by Universities/Institutes
Systemic Lupus Erythematosus - Pipeline Products Glance
Systemic Lupus Erythematosus - Products under Development by Companies
Systemic Lupus Erythematosus - Products under Investigation by Universities/Institutes
Systemic Lupus Erythematosus - Companies Involved in Therapeutics Development
Systemic Lupus Erythematosus - Therapeutics Assessment
Drug Profiles
Systemic Lupus Erythematosus - Dormant Projects
Systemic Lupus Erythematosus - Discontinued Products
Systemic Lupus Erythematosus - Product Development Milestones
Appendix 405

LIST OF TABLES

Number of Products under Development for Systemic Lupus Erythematosus, H2 2016
Number of Products under Development for Systemic Lupus Erythematosus - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Investigation by Universities/Institutes, H2 2016
Systemic Lupus Erythematosus - Pipeline by AbbVie Inc, H2 2016
Systemic Lupus Erythematosus - Pipeline by Ablynx NV, H2 2016
Systemic Lupus Erythematosus - Pipeline by ACEA Biosciences, Inc., H2 2016
Systemic Lupus Erythematosus - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2016
Systemic Lupus Erythematosus - Pipeline by Actelion Ltd, H2 2016
Systemic Lupus Erythematosus - Pipeline by AiCuris GmbH and Co KG, H2 2016
Systemic Lupus Erythematosus - Pipeline by Amgen Inc., H2 2016
Systemic Lupus Erythematosus - Pipeline by Anthera Pharmaceuticals Inc, H2 2016
Systemic Lupus Erythematosus - Pipeline by Argos Therapeutics, Inc., H2 2016
Systemic Lupus Erythematosus - Pipeline by Asahi Kasei Pharma Corp., H2 2016
Systemic Lupus Erythematosus - Pipeline by Astellas Pharma Inc., H2 2016
Systemic Lupus Erythematosus - Pipeline by Aurinia Pharmaceuticals Inc, H2 2016
Systemic Lupus Erythematosus - Pipeline by Azano Pharmaceuticals Inc., H2 2016
Systemic Lupus Erythematosus - Pipeline by Biogen Inc, H2 2016
Systemic Lupus Erythematosus - Pipeline by Biotest AG, H2 2016
Systemic Lupus Erythematosus - Pipeline by Boehringer Ingelheim GmbH, H2 2016
Systemic Lupus Erythematosus - Pipeline by Bristol-Myers Squibb Company, H2 2016
Systemic Lupus Erythematosus - Pipeline by Celgene Corporation, H2 2016
Systemic Lupus Erythematosus - Pipeline by Cellular Biomedicine Group, Inc., H2 2016
Systemic Lupus Erythematosus - Pipeline by CuraVac, Inc., H2 2016
Systemic Lupus Erythematosus - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
Systemic Lupus Erythematosus - Pipeline by Deltanoid Pharmaceuticals Inc., H2 2016
Systemic Lupus Erythematosus - Pipeline by Eisai Co., Ltd., H2 2016
Systemic Lupus Erythematosus - Pipeline by Eli Lilly and Company, H2 2016
Systemic Lupus Erythematosus - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Systemic Lupus Erythematosus - Pipeline by Genentech Inc, H2 2016
Systemic Lupus Erythematosus - Pipeline by Genosco, H2 2016
Systemic Lupus Erythematosus - Pipeline by Genovax S.r.l., H2 2016
Systemic Lupus Erythematosus - Pipeline by GlaxoSmithKline Plc, H2 2016
Systemic Lupus Erythematosus - Pipeline by HanAll Biopharma Co., Ltd., H2 2016
Systemic Lupus Erythematosus - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016
Systemic Lupus Erythematosus - Pipeline by Iltoo Pharma, H2 2016
Systemic Lupus Erythematosus - Pipeline by ImmuNext, Inc., H2 2016
Systemic Lupus Erythematosus - Pipeline by Immungenetics AG, H2 2016
Systemic Lupus Erythematosus - Pipeline by Immunomedics, Inc., H2 2016
Systemic Lupus Erythematosus - Pipeline by Immupharma Plc, H2 2016
Systemic Lupus Erythematosus - Pipeline by Invion Limited, H2 2016
Systemic Lupus Erythematosus - Pipeline by Johnson & Johnson, H2 2016
Systemic Lupus Erythematosus - Pipeline by Kadmon Corporation, LLC, H2 2016
Systemic Lupus Erythematosus - Pipeline by Karyopharm Therapeutics, Inc., H2 2016
Systemic Lupus Erythematosus - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016
Systemic Lupus Erythematosus - Pipeline by KPI Therapeutics, Inc., H2 2016
Systemic Lupus Erythematosus - Pipeline by Lead Discovery Center GmbH, H2 2016
Systemic Lupus Erythematosus - Pipeline by LSK BioPartners, Inc., H2 2016
Systemic Lupus Erythematosus - Pipeline by MacroGenics, Inc., H2 2016
Systemic Lupus Erythematosus - Pipeline by MedAnnex Ltd, H2 2016
Systemic Lupus Erythematosus - Pipeline by Medestea Research & Production S.p.A., H2 2016
Systemic Lupus Erythematosus - Pipeline by MedImmune LLC, H2 2016
Systemic Lupus Erythematosus - Pipeline by Merck KGaA, H2 2016
Systemic Lupus Erythematosus - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
Systemic Lupus Erythematosus - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
Systemic Lupus Erythematosus - Pipeline by Mount Tam Biotechnologies Inc, H2 2016
Systemic Lupus Erythematosus - Pipeline by Neovacs SA, H2 2016
Systemic Lupus Erythematosus - Pipeline by Nippon Chemiphar Co., Ltd., H2 2016
Systemic Lupus Erythematosus - Pipeline by Nuevolution AB, H2 2016
Systemic Lupus Erythematosus - Pipeline by Omeros Corporation, H2 2016
Systemic Lupus Erythematosus - Pipeline by Parvus Therapeutics, Inc., H2 2016
Systemic Lupus Erythematosus - Pipeline by Pfizer Inc., H2 2016
Systemic Lupus Erythematosus - Pipeline by Principia Biopharma Inc., H2 2016
Systemic Lupus Erythematosus - Pipeline by Ra Pharmaceuticals, Inc., H2 2016
Systemic Lupus Erythematosus - Pipeline by RedHill Biopharma Ltd., H2 2016
Systemic Lupus Erythematosus - Pipeline by Redx Pharma Plc, H2 2016
Systemic Lupus Erythematosus - Pipeline by Resolve Therapeutics, LLC, H2 2016
Systemic Lupus Erythematosus - Pipeline by Sanofi, H2 2016
Systemic Lupus Erythematosus - Pipeline by Sarepta Therapeutics, Inc., H2 2016
Systemic Lupus Erythematosus - Pipeline by SBI Biotech Co., Ltd., H2 2016
Systemic Lupus Erythematosus - Pipeline by Seattle Genetics, Inc., H2 2016
Systemic Lupus Erythematosus - Pipeline by Shire Plc, H2 2016
Systemic Lupus Erythematosus - Pipeline by Stemline Therapeutics, Inc., H2 2016
Systemic Lupus Erythematosus - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
Systemic Lupus Erythematosus - Pipeline by TheraMAB LLC, H2 2016
Systemic Lupus Erythematosus - Pipeline by Therapix Biosciences Ltd., H2 2016
Systemic Lupus Erythematosus - Pipeline by Thunderbolt Pharma Inc, H2 2016
Systemic Lupus Erythematosus - Pipeline by TxCell SA, H2 2016
Systemic Lupus Erythematosus - Pipeline by UCB SA, H2 2016
Systemic Lupus Erythematosus - Pipeline by Xencor, Inc., H2 2016
Systemic Lupus Erythematosus - Pipeline by XTL Biopharmaceuticals Ltd, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Systemic Lupus Erythematosus - Dormant Projects, H2 2016
Systemic Lupus Erythematosus - Dormant Projects (Contd..1), H2 2016
Systemic Lupus Erythematosus - Dormant Projects (Contd..2), H2 2016
Systemic Lupus Erythematosus - Dormant Projects (Contd..3), H2 2016
Systemic Lupus Erythematosus - Dormant Projects (Contd..4), H2 2016
Systemic Lupus Erythematosus - Dormant Projects (Contd..5), H2 2016
Systemic Lupus Erythematosus - Dormant Projects (Contd..6), H2 2016
Systemic Lupus Erythematosus - Dormant Projects (Contd..7), H2 2016
Systemic Lupus Erythematosus - Dormant Projects (Contd..8), H2 2016
Systemic Lupus Erythematosus - Discontinued Products, H2 2016
Systemic Lupus Erythematosus - Discontinued Products (Contd..1), H2 2016 404

LIST OF FIGURES

Number of Products under Development for Systemic Lupus Erythematosus, H2 2016
Number of Products under Development for Systemic Lupus Erythematosus - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Systemic Lupus Erythematosus Therapy Area Pipeline Report US$ 1,495.00 Sep, 2010 · 187 pages

Ask Your Question

Systemic Lupus Erythematosus - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: